From: Association of renal resistive indices with kidney disease progression and mortality
Univariate analysis | |||
---|---|---|---|
HR | 95% Confidence Interval | P | |
RRI | 1.05 | 1.02–1.09 | 0.003 |
Age | 1.01 | 0.98–1.03 | 0.762 |
Sex ( Ref: Male) | 0.60 | 0.25–1.44 | 0.255 |
Diabetes | 1.95 | 1.03–3.67 | 0.040 |
Dyslipidemia | 1.65 | 0.69–3.93 | 0.259 |
Obesity | 0.95 | 0.49–1.85 | 0.880 |
CAD | 1.65 | 0.87–3.13 | 0.127 |
Heart failure | 1.76 | 0.69–4.49 | 0.238 |
Stroke | 0.83 | 0.20–3.45 | 0.797 |
eGFR, mL/min | 0.90 | 0.88–0.93 | < 0.001 |
ACR, g/g | 1.51 | 1.36–1.69 | < 0.001 |
RAAS inhibitors | 0.49 | 0.27–0.93 | 0.028 |
Statins | 0.76 | 0.41–1.44 | 0.404 |
Beta-blockers | 1.94 | 0.98–3.83 | 0.056 |
Antiaggregants | 1.56 | 0.83–2.91 | 0.167 |
PPIs | 1.23 | 0.63–2.42 | 0.548 |
BP control < 140/90 | 0.44 | 0.23–0.82 | 0.010 |
Compliance to salt reduction | 0.22 | 0.09–0.50 | < 0.001 |
HbA1c reduction in patients with diabetes | 0.73 | 0.32–1.65 | 0.442 |
Smoking cessation in smokers | 0.56 | 0.13–2.46 | 0.443 |
Number of visits over follow-up duration | 7.89 | 4.63, 13.43 | < 0.001 |